Annual report pursuant to Section 13 and 15(d)

License and Collaboration Agreements, Nyxol License Agreement (Details)

v3.23.1
License and Collaboration Agreements, Nyxol License Agreement (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Nov. 06, 2022
USD ($)
Nov. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Performanceobligation
Dec. 31, 2021
USD ($)
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Beginning Balance     $ 0  
Revenue recognized     39,850 $ 589
Ending Balance     3,552 0
Nyxol License Agreement [Member]        
Collaboration and License Agreement [Abstract]        
Non-refundable cash payment received   $ 35,000 $ 35,000  
Maximum amount of payments receivable for development, regulatory and commercial milestones $ 130,000      
First potential payments to be received 10,000      
Maximum percentage of tiered royalties receivable     20.00%  
Number of distinct performance obligations | Performanceobligation     2  
Aggregate transaction price to be recognized $ 40,200      
Period of non-cancellation window agreement 120 days      
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Beginning Balance     $ 0  
Revenue recognized     39,800  
Execution of Nyxol License Agreement and one-time non-refundable payment   $ (35,000) (35,000)  
Ending Balance     3,552 $ 0
Nyxol License Agreement [Member] | License Transfer Fee [Member]        
Collaboration and License Agreement [Abstract]        
Aggregate transaction price to be recognized $ 35,000      
Estimated standalone selling price for license agreement 287,800      
Transaction price allocation of ESSP obligations 39,500      
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Revenue recognized     39,519  
Reclassification to accounts receivable related to costs billed under the Nyxol License Agreement     (1,298)  
Nyxol License Agreement [Member] | Research and Development Services [Member]        
Collaboration and License Agreement [Abstract]        
Aggregate transaction price to be recognized 5,200      
Estimated standalone selling price for license agreement 5,200      
Transaction price allocation of ESSP obligations $ 700      
Reconciliation of Closing Balance of Contract Asset [Abstract]        
Revenue recognized     $ 331